Healthcare sector | Medical Devices industry
| Price | $6.44 |
|---|---|
| Shares Outstanding | 41.27M |
| All-Time Low | $6.32 |
| 52-Week Low | $6.32 |
| Net Cash / Share | $4.65 |
|---|---|
| Net Current Assets / Share | $6.09 |
| Net Tangible Assets / Share | $6.68 |
| Shares Outstanding Ave Change (Annual) | 13.89% |
| Shares Δ YoY | 11.87% |
| Avg CA Burn (Annual %) | 25.32% (as of 3-8-2026) |
| Avg CA Burn (Quarterly %) | -0.54% (as of 3-8-2026) |
| Max Earning Power / Share | $-1.91 |
|---|---|
| Adjusted Earning Power |
$-2.11
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
|
| Non-Cash Charges to Market Cap |
0.28%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
|
| Avg EBITDA (5Y) | 0 (as of 3-8-2026) |
| Avg EBITDA (5Q) | 0 (as of 3-8-2026) |
| Avg Net Income (5Y) | -47.9M (as of 3-8-2026) |
| Avg Net Income (5Q) | -9M (as of 3-8-2026) |
| Dividend indicators | Value | Date |
|---|---|---|
| Current Dividend Streak | No | 3-8-2026 |
| Consecutive Years Paid | No | 3-8-2026 |
| Pays Dividend | No | 3-8-2026 |
| Income indicators | Value | Date |
|---|---|---|
| EBITDA Positive | No | 3-8-2026 |
| Net Income Positive | No | 3-8-2026 |
| Current Dividend Streak | No | 3-8-2026 |
Pick a metric to view its history table and chart.
Formula: Tangible Book Value / shares from balance statements. Includes 6 quarterly + 4 annual.
Chart plots one TBV / Share point per report date (duplicate same-date annual/quarterly rows are merged).
| Report Date | Period | TBV / Share | Tangible Book Value | Shares Used |
|---|---|---|---|---|
| 2025-12-31 | Quarterly | $6.68 | 275.7M ($275,683,000) | 41.2M (41,242,005) |
| 2025-09-30 | Quarterly | $6.72 | 276M ($275,970,000) | 41.1M (41,081,550) |
| 2025-06-30 | Quarterly | $6.80 | 278M ($278,012,000) | 40.9M (40,913,380) |
| 2025-03-31 | Quarterly | $6.88 | 279.3M ($279,316,000) | 40.6M (40,588,540) |
| 2024-12-31 | Quarterly | $6.96 | 281.2M ($281,238,000) | 40.4M (40,428,220) |
| 2024-12-31 | Annual | $6.96 | 281.2M ($281,238,000) | 40.4M (40,428,220) |
| 2024-09-30 | Quarterly | $6.89 | 277.3M ($277,261,000) | 40.3M (40,254,105) |
| 2023-12-31 | Annual | $4.44 | 160.4M ($160,362,000) | 36.1M (36,139,513) |
| 2022-12-31 | Annual | $3.18 | 89.9M ($89,902,000) | 28.3M (28,268,389) |
| 2021-12-31 | Annual | $5.05 | 138.2M ($138,242,000) | 27.4M (27,366,746) |
Revenue from income statements. Includes 4 annual.
Chart plots one annual Revenue point per report date.
| Report Date | Revenue |
|---|---|
| 2024-12-31 | 139.9M ($139,927,000) |
| 2023-12-31 | 89.1M ($89,077,000) |
| 2022-12-31 | 49M ($49,005,000) |
| 2021-12-31 | 22.6M ($22,593,000) |
Historical cash dividends per share from Yahoo ex-dividend dates.
| Date | Dividend / Share |
|---|---|
| No dividend payment history available yet | |
| Date | Shares Outstanding | Delta |
|---|---|---|
| 2026-03-06 | 41,266,335 | +149,695 |
| 2025-11-07 | 41,116,640 | +200,677 |
| 2025-09-17 | 40,915,963 | -37 |
Latest short-interest change: 5,531,006 shares (14.06% of float) | Days to cover: 4.99
| Date | Short Interest | Delta | Δ % |
|---|---|---|---|
| 2026-03-12 | 5,531,006 shares | +172,267 | +3.21% |
| 2026-02-27 | 5,358,739 shares | +1,214,104 | +29.29% |
| 2026-02-11 | 4,144,635 shares | -639,227 | -13.36% |
Volume/ratio use shares outstanding as of the event date (frozen).
| Date | Volume | Shares Outstanding | Volume / Shares | Price |
|---|---|---|---|---|
| No interesting volume events | ||||
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.